Last reviewed 2026-05-18 · How we verify

Electrofusion DC vaccine

Beth Israel Deaconess Medical Center · Phase 1 active Biologic Quality 35/100

Electrofusion DC vaccine is a Dendritic cell vaccine Biologic drug developed by Beth Israel Deaconess Medical Center. It is currently in Phase 1 development.

Fuses patient dendritic cells with tumor cells using electrofusion to create a personalized vaccine that activates T-cell responses against cancer.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Electrofusion DC vaccine
Sponsor	Beth Israel Deaconess Medical Center
Drug class	Dendritic cell vaccine
Modality	Biologic
Phase	Phase 1

Mechanism of action

The vaccine is created by using electrical pulses to fuse patient-derived dendritic cells with autologous tumor cells. This fusion allows dendritic cells to present tumor antigens to the immune system, activating cytotoxic T-lymphocytes to recognize and attack cancer cells bearing those antigens.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Electrofusion DC vaccine CI brief — competitive landscape report
Electrofusion DC vaccine updates RSS · CI watch RSS
Beth Israel Deaconess Medical Center portfolio CI

Frequently asked questions about Electrofusion DC vaccine

What is Electrofusion DC vaccine?

Electrofusion DC vaccine is a Dendritic cell vaccine drug developed by Beth Israel Deaconess Medical Center.

How does Electrofusion DC vaccine work?

Fuses patient dendritic cells with tumor cells using electrofusion to create a personalized vaccine that activates T-cell responses against cancer.

Who makes Electrofusion DC vaccine?

Electrofusion DC vaccine is developed by Beth Israel Deaconess Medical Center (see full Beth Israel Deaconess Medical Center pipeline at /company/beth-israel-deaconess-medical-center).

What drug class is Electrofusion DC vaccine in?

Electrofusion DC vaccine belongs to the Dendritic cell vaccine class. See all Dendritic cell vaccine drugs at /class/dendritic-cell-vaccine.

What development phase is Electrofusion DC vaccine in?

Electrofusion DC vaccine is in Phase 1.

Drug class: All Dendritic cell vaccine drugs
Manufacturer: Beth Israel Deaconess Medical Center — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing